Skip to main content
Virbac logo

Virbac — Investor Relations & Filings

Ticker · FR000 ISIN · FR0000031577 LEI · 969500QQ1X5XHG649644 PA Manufacturing
Open in API
Filings indexed 975 across all filing types
Latest filing 2021-09-15 Interim / Quarterly Rep…
Country FR France
Listing PA FR000

About Virbac

https://corporate.virbac.com/home.html

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company provides veterinarians, farmers, and pet owners with a comprehensive range of products and services. Its portfolio of innovative solutions covers the majority of animal species and diseases, with a focus on both companion and farm animals. Key product areas include vaccines, dermatology, parasite control, dental care, nutrition, and diagnostics. Through its international R&D network, Virbac develops solutions to prevent, diagnose, and treat animal pathologies, contributing to animal welfare and supporting sustainable farming.

Recent filings

Filing Released Lang Actions
Virbac : mise à disposition du rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport financier semestriel' (Half-year financial report) for the period ending June 30, 2021. It contains detailed management commentary on business activities, major events, and financial data analysis, which is characteristic of an interim financial report. It is not a mere announcement (RPA) as it contains substantive financial analysis and operational details. H1 2021
2021-09-15 French
Virbac : availability of half year report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-yearly financial report' and covers the period ending June 30, 2021. It contains detailed management commentary, analysis of consolidated financial statements, and performance metrics by segment. It is a comprehensive interim report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-09-15 English
Virbac: Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business
Earnings Release Classification · 95% confidence The document is a press release detailing the company's financial performance for the first half of 2021. It includes consolidated financial figures (revenue, operating profit, net profit, debt) and management's analysis of these results. While it contains financial data, it is structured as an earnings release (ER) rather than a full interim report (IR), as it is a summary announcement of results rather than the complete statutory filing. It also includes an invitation to an analyst presentation, which is standard for an earnings release. H1 2021
2021-09-15 English
Virbac: Résultat opérationnel courant du premier semestre 2021 en très forte croissance qui reflète la bonne tenue du marché et le dynamisme de notre activité
Interim / Quarterly Report Classification · 95% confidence The document is a press release titled 'Résultat opérationnel courant du premier semestre 2021' (Operating income for the first half of 2021). It provides detailed financial highlights, including consolidated figures for the period ending June 30, 2021, and management's analysis of business performance, trends, and outlook. While it is a press release, it contains substantive financial data and analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR) rather than a simple announcement of a report (RPA), as it provides the actual financial results themselves. H1 2021
2021-09-15 French
Virbac : Aquaculture : Virbac strengthens its position in Centrovet
M&A Activity Classification · 95% confidence The document announces that Virbac has acquired additional shares in the Centrovet group, increasing its stake to 66%. This action directly relates to a change in ownership structure and a significant corporate transaction involving the acquisition of another entity's shares. This falls under the category of Merger & Acquisition (M&A) activity or a significant transaction affecting capital structure. Given the options, 'M&A Activity' (TAR) is the most appropriate fit for announcing the acquisition of a controlling stake in another company, even if it's a phased acquisition. It is not a standard financial report (10-K, IR, ER) or a simple capital change (SHA/POS), but a strategic transaction.
2021-09-13 English
Virbac : Aquaculture : Virbac renforce ses positions dans Centrovet
M&A Activity Classification · 98% confidence The document announces that Virbac has acquired additional shares (15%) in Centrovet, increasing its stake to 66%. It details the strategic rationale (aquaculture market in Chile), the financial consideration ($17.7 million USD paid in cash), and the accounting treatment (already consolidated 100% since 2012). This is a clear announcement regarding a significant corporate transaction involving the acquisition of equity in another company, which falls under Mergers & Acquisitions (M&A) activity. The appropriate code is TAR (M&A Activity). The document is short and is an announcement, not a comprehensive report.
2021-09-13 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.